Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay

[1]  Wentao Yang,et al.  A novel highly sensitive and specific flow cytometry system for cervical cancer screening. , 2015, Gynecologic oncology.

[2]  A. Deters,et al.  A jack-of-all-trades: 2-mercaptosuccinic acid , 2015, Applied Microbiology and Biotechnology.

[3]  Yimin Li,et al.  A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine , 2015, Applied Microbiology and Biotechnology.

[4]  Junsoo Park,et al.  Measurement of antibodies to varicella-zoster virus using a virus-free fluorescent-antibody-to-membrane-antigen (FAMA) test. , 2015, Journal of microbiology and biotechnology.

[5]  J. Kang,et al.  Seroepidemiology of varicella-zoster virus in Korean adolescents and adults using fluorescent antibody to membrane antigen test , 2014, Epidemiology and Infection.

[6]  P. Ahtoy,et al.  Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab , 2013, Neurology.

[7]  B. Gruhn,et al.  Evaluation of Three Commercial Varicella-Zoster Virus IgG Enzyme-Linked Immunosorbent Assays in Comparison to the Fluorescent-Antibody-to-Membrane-Antigen Test , 2012, Clinical and Vaccine Immunology.

[8]  K. Schmader,et al.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study , 2010, Canadian Medical Association Journal.

[9]  A. Baiker,et al.  Early detection of Varicella-Zoster Virus (VZV)-specific T-cells before seroconversion in primary varicella infection: case report , 2010, Virology Journal.

[10]  J. Seward,et al.  Varicella Prevention in the United States: A Review of Successes and Challenges , 2008, Pediatrics.

[11]  K. Edwards,et al.  Primary vaccine failure after 1 dose of varicella vaccine in healthy children. , 2008, The Journal of infectious diseases.

[12]  L. Mascola,et al.  Changing varicella epidemiology in active surveillance sites--United States, 1995-2005. , 2008, The Journal of infectious diseases.

[13]  K. Sawanyawisuth,et al.  MRI findings in acute disseminated encephalomyelitis following varicella infection in an adult , 2007, Journal of Clinical Neuroscience.

[14]  N. Chirmule,et al.  The optimization and validation of the glycoprotein ELISA assay for quantitative varicella‐zoster virus (VZV) antibody detection , 2006, Journal of medical virology.

[15]  P. Wutzler,et al.  Serological Detection of Varicella-Zoster Virus-Specific Immunoglobulin G by an Enzyme-Linked Immunosorbent Assay Using Glycoprotein Antigen , 2006, Journal of Clinical Microbiology.

[16]  J. Gray,et al.  Performance of a Time-Resolved Fluorescence Immunoassay for Measuring Varicella-Zoster Virus Immunoglobulin G Levels in Adults and Comparison with Commercial Enzyme Immunoassays and Merck Glycoprotein Enzyme Immunoassay , 2006, Clinical and Vaccine Immunology.

[17]  P. Wutzler,et al.  Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test. , 2004, Journal of virological methods.

[18]  E. Shapiro,et al.  The effectiveness of the varicella vaccine in clinical practice. , 2001, The New England journal of medicine.

[19]  S. Straus,et al.  Varicella-zoster virus glycoproteins E and I expressed in insect cells form a heterodimer that requires the N-terminal domain of glycoprotein I. , 1997, Virology.

[20]  Rita R. Colwell,et al.  A simplified immunofluorescence technique for detection of viable cells of Vibrio cholerae O1 and O139 , 1995 .

[21]  R Platt,et al.  The epidemiology of varicella and its complications. , 1995, The Journal of infectious diseases.

[22]  P. LaRussa,et al.  Detection of antibodies to varicella-zoster virus using a latex agglutination assay. , 1994, Clinical and diagnostic virology.

[23]  D. Morton,et al.  Antibody assays suitable for assessing immune responses to live varicella vaccine. , 1991, Vaccine.

[24]  W. Miller,et al.  Sensitive enzyme‐linked immunosorbent assay for antibody to varicella‐zoster virus using purified VZV glycoprotein antigen , 1990, Journal of medical virology.

[25]  R. Holzman,et al.  Comparison of five assays for antibody to varicella-zoster virus and the fluorescent-antibody-to-membrane-antigen test , 1987, Journal of clinical microbiology.

[26]  P. Keller,et al.  Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. , 1986, Journal of virological methods.

[27]  A. Davison,et al.  New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products , 1986, Journal of virology.

[28]  H. Yabuuchi,et al.  A simplified immunofluorescence technique for antibody to varicella-zoster membrane antigen (FAMA). , 1984, Biken journal.

[29]  P. Brunell,et al.  Enzyme-linked immunosorbent assay for susceptibility to varicella. , 1983, The Journal of infectious diseases.

[30]  C. Grose,et al.  Complement-enhanced neutralizing antibody response to varicella-zoster virus. , 1979, The Journal of infectious diseases.

[31]  A. Gershon,et al.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. , 1974, The Journal of infectious diseases.

[32]  D. Shaw,et al.  Neutralization tests with varicella-zoster virus , 1969, Journal of Hygiene.

[33]  M. Gershon,et al.  Perspectives on vaccines against varicella-zoster virus infections. , 2010, Current topics in microbiology and immunology.

[34]  R. Ellis,et al.  Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults. , 1997, Vaccine.

[35]  A. Gershon.  Development of live attenuated varicella vaccine. , 1995, Proceedings of the Association of American Physicians.